![](/img/cover-not-exists.png)
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Powles, T., Lackner, M. R., Oudard, S., Escudier, B., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., Ravaud, A., Lin, W., OKeeffe, B., Wang, Y., Lu, S., SpoerkeLanguage:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2015.64.8808
Date:
March, 2016
File:
PDF, 1.49 MB
english, 2016